SPDR FTSE UK All Share UCITS ETF (GB:FTAD) Price & Chart
GB:FTAD ETF Chart & Stats
£695.25
At close: 4:00 PM EST- Day’s Range
- GBP 690.31 - GBP 695.70
- 52-Week Range
- GBP 609.40 - GBP 727.11
- Previous Close
- GBP 688.70
- Volume
- 25.47K
- Average Volume (3M)
- 29.60K
- AUM
- 328.62M
- NAV
- 6.89
- Expense Ratio
- 0.20%
- Holdings Count
- 496
- Beta
- 1.00
- Inception Date
- Apr 26, 2018
- Last Dividend Ex-Date
- Sep 21, 2026
- Dividend Yield
- (2988852.93%)
- Shares Outstanding
- 48,273,376
- Standard Deviation
- N/A
ETF Overview
SPDR FTSE UK All Share UCITS ETF
The SPDR FTSE UK All Share UCITS ETF, trading under the ticker GB:FTAD, offers investors a comprehensive gateway to the entire UK equity market. This ETF stands out in the "Size and Style" category, targeting the "Total Market" with a "Broad-based" approach, making it an ideal choice for those looking to capture the full spectrum of opportunities within the UK economy. By mirroring the performance of the FTSE All-Share Index, the fund provides exposure to a diversified range of UK-listed companies, from large blue-chip stalwarts to burgeoning small-cap enterprises. Designed to deliver a balance between risk and reward, the SPDR FTSE UK All Share UCITS ETF caters to investors seeking a holistic investment in UK equities. The fund's broad-based niche ensures that it encapsulates the dynamic nature of the market, adapting to shifts in economic trends and corporate performance across various sectors. With its strategic focus, the ETF not only enhances portfolio diversification but also offers a cost-effective solution for those aiming to harness the potential of the UK stock market in its entirety. Whether you're a seasoned investor or new to the market, this ETF provides a robust platform for capitalizing on the growth prospects of the United Kingdom's corporate landscape.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- SPDR
- Index Tracked
- FTSE All-Share
- Ticker Symbol
- GB:FTAD
GB:FTAD ETF News
AstraZeneca Advances New Ovarian Cancer Combination Study
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian
3d agoAZN
AstraZeneca Advances China Cancer Trial as Durvalumab Takes Center Stage
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction
3d agoAZN
GB:FTAD ETF FAQ
What was GB:FTAD’s price range in the past 12 months?
GB:FTAD’s lowest price in the past 12 months was GBP 609.40 and its highest was GBP 727.11.
What is the AUM of GB:FTAD?
As of Nov 06, 2026, the AUM of GB:FTAD is £328.62M.
Is GB:FTAD overvalued?
Based on Wall Street analyst price targets for GB:FTAD’s holdings, GB:FTAD’s price is currently undervalued.
Does GB:FTAD pay dividends?
Yes. GB:FTAD pays dividends semi-annually. Its most recent dividend was £13,950,000.00 per share, and its annual dividend yield is 2988852.93%. See more information on GB:FTAD dividends here.
How many shares outstanding does GB:FTAD have?
GB:FTAD has 48,273,376 shares outstanding.
GB:FTAD ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| HSBAHsbc Holdings Plc (UK) | 7.70% |
| SHELShell plc (UK) | 7.59% |
| AZNAstraZeneca plc | 7.24% |
| ULVRUnilever Plc (UK) | 3.60% |
| RRRolls-Royce Holdings | 3.57% |
| BATSBritish American Tobacco (UK) | 3.29% |
| BPBP p.l.c. | 3.06% |
| GSKGlaxoSmithKline plc (UK) | 2.59% |
| RIORio Tinto (LSE:RIO) | 2.23% |
| NGNational Grid (Uk) | 2.21% |
| Total | 43.10% |
